All News

Explore the critical role of pharmacists in improving cardiovascular health and addressing mortality trends in underserved communities.

A new drug, DR10624, shows promise in reducing triglycerides and liver fat, offering hope for patients with severe hypertriglyceridemia and fatty liver disease.

Shoa Clarke, MD, PhD, discusses the need for improved cholesterol testing and treatment in young adults, emphasizing the vital role of primary care teams and pharmacists in early intervention and adherence.

Explore the link between chronic kidney disease and cardiovascular risk, highlighting the importance of GFR and albuminuria in patient care.

Explore the need for integrated approaches in cardiovascular and kidney health to combat rising mortality rates and improve patient outcomes.

Experts at AHA 2025 advocate for integrated care in T2D and CKD, emphasizing cardiovascular risk management to enhance patient outcomes.

Discover how Sotatercept impacts cardiovascular health and its potential benefits for patients with pulmonary arterial hypertension (PAH) in this insightful article.

Pharmacists play a vital role in managing cardiovascular health, addressing medication adherence, and educating patients, said Zia Ul Haq, MPH, MBBS.

Consistent use of continuous glucose monitoring (CGM) significantly improves glycemic control in adults with type 2 diabetes (T2D).

SGLT2 inhibitors significantly reduce atrial fibrillation risk and improve heart failure outcomes, outperforming GLP-1 agonists in cardiovascular benefits.

SHR-A1811 shows significant antitumor activity in early-stage HER2+ breast cancer, both alone and with pyrotinib, promising improved treatment outcomes.

Oncology pharmacy evolves rapidly, emphasizing the need for pharmacists to stay informed and reflect on personal growth for better patient care.

Maternal type 1 diabetes may influence children's DNA, potentially reducing their risk of developing islet autoimmunity.

Knowledge of serotype prevalence and virulence can optimize the management of community-acquired pneumonia.

New findings suggest omitting radiation therapy in postmastectomy breast cancer treatment enhances survival, emphasizing the role of systemic therapies.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

Maintaining cardiovascular health significantly reduces dementia risk in adults with type 2 diabetes, highlighting the heart-brain connection for cognitive protection.

Leukogene's M2T-CD33 gains FDA orphan drug status, promising a novel immunotherapy approach for acute myeloid leukemia treatment.

The move continues the push towards most favored nation (MFN) status, lowering the prices of glucagon-like peptide-1 (GLP-1s) drugs for Medicare recipients.

Moderate to severe obstructive sleep apnea significantly increases the risk of cerebral microbleeds.

A genomic screening initiative identified patients harboring a familial hypercholesterolemia genetic variation and directed them toward LDL-C-lowering therapies, inducing meaningful reductions.

Gedatolisib shows promise in enhancing progression-free survival for HR+/HER2– breast cancer patients resistant to standard therapies, as revealed in ESMO 2025.

Combining GLP-1 RA therapy with healthy lifestyle habits significantly reduces cardiovascular risk in type 2 diabetes patients, enhancing heart health outcomes.

As an adjunct to depression treatment, lumateperone reduced depressive symptoms and improved quality of life.

Enfortumab vedotin-ejfv has transformed treatment in locally advanced and metastatic urothelial carcinoma from decades-long platinum-based chemotherapy to the new standard of care combination of antibody-drug conjugate and PD-1/PD-L1 inhibitor.

Discover the importance of early screening for type 1 diabetes and how it can prevent life-threatening complications.

Low-dose aspirin significantly reduces heart attack, stroke, and death risks in adults with type 2 diabetes and elevated cardiovascular risk.

Although further data will be presented in 2026, lifileucel shows promise as a 1-time treatment for advanced non–small cell lung cancer (NSCLC).